Roquefort Therapeutics plc (LON:ROQ – Get Free Report)’s stock price traded down 3.3% during trading on Tuesday . The company traded as low as GBX 4.10 ($0.05) and last traded at GBX 4.35 ($0.06). 761,441 shares traded hands during trading, an increase of 27% from the average session volume of 600,833 shares. The stock had previously closed at GBX 4.50 ($0.06).
Roquefort Therapeutics Price Performance
The stock has a market capitalization of £5.62 million, a price-to-earnings ratio of -435.00 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock has a 50-day moving average price of GBX 4.29 and a 200 day moving average price of GBX 4.20.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- What Investors Need to Know About Upcoming IPOs
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
